Literature DB >> 25313448

Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.

Tara R Henning1, Debra Hanson, Sundaram A Vishwanathan, Katherine Butler, Charles Dobard, Gerardo Garcia-Lerma, Jessica Radzio, James Smith, Janet M McNicholl, Ellen N Kersh.   

Abstract

The repeat low-dose virus challenge model is commonly used in nonhuman primate studies of HIV transmission and biomedical preventions. For some viruses or challenge routes, it is uncertain whether the repeated exposure design might induce virus-directed innate or adaptive immunity that could affect infection or viremic outcomes. Retrospective cohorts of male Indian rhesus (n=40) and female pigtail (n=46) macaques enrolled in repeat low-dose rectal or vaginal SHIV(SF162p3) challenge studies, respectively, were studied to compare the relationship between the number of previous exposures and peak plasma SHIV RNA levels or viral load area under the curve (AUC), surrogate markers of viral control. Repeated mucosal exposures of 10 or 50 TCID50 of virus for rectal and vaginal exposures, respectively, were performed. Virus levels were measured by quantitative reverse-transcriptase real-time PCR. The cumulative number of SHIV(SF162p3) exposures did not correlate with observed peak virus levels or with AUC in rectally challenged rhesus macaques [peak: rho (ρ)=0.04, p=0.8; AUC: ρ=0.33, p=0.06] or vaginally challenged pigtail macaques (peak: ρ=-0.09, p=0.7; AUC: ρ=0.11, p=0.6). Infections in these models occur independently of exposure history and provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia. These data also indicate that both the vaginal and rectal repeated low-dose virus exposure models using SHIV(SF162p3) provide a reliable system for nonhuman primate studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25313448      PMCID: PMC4208603          DOI: 10.1089/aid.2014.0238

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

Authors:  J M Harouse; A Gettie; R C Tan; J Blanchard; C Cheng-Mayer
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).

Authors:  Bapi Pahar; Xiaolei Wang; Jason Dufour; Andrew A Lackner; Ronald S Veazey
Journal:  Virology       Date:  2007-02-16       Impact factor: 3.616

3.  Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations.

Authors:  Michael Aidoo; Ronald A Otten; Vanessa Rodriguez; Carlos A Sariol; Melween Martinez; Edmundo Kraiselburd; Harriet Robinson; Thomas Folks; Salvatore Butera; Dennis Ellenberger
Journal:  Vaccine       Date:  2007-06-29       Impact factor: 3.641

4.  Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3).

Authors:  J M Harouse; A Gettie; T Eshetu; R C Tan; R Bohm; J Blanchard; G Baskin; C Cheng-Mayer
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates.

Authors:  Ron A Otten; Debra R Adams; Caryn N Kim; Eddie Jackson; Jennifer K Pullium; Kemba Lee; Lisa A Grohskopf; Michael Monsour; Sal Butera; Thomas M Folks
Journal:  J Infect Dis       Date:  2004-12-09       Impact factor: 5.226

6.  A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations.

Authors:  Zhong-Min Ma; Kristina Abel; Tracy Rourke; Yichuan Wang; Christopher J Miller
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya.

Authors:  K R Fowke; N J Nagelkerke; J Kimani; J N Simonsen; A O Anzala; J J Bwayo; K S MacDonald; E N Ngugi; F A Plummer
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Intrarectal transmission of simian immunodeficiency virus in rhesus macaques: selective amplification and host responses to transient or persistent viremia.

Authors:  P Trivedi; D Horejsh; S B Hinds; I I Hinds PW; M S Wu; M S Salvato; C D Pauza
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.

Authors:  Charles Dobard; Sunita Sharma; Urvi M Parikh; Rolieria West; Andrew Taylor; Amy Martin; Chou-Pong Pau; Debra L Hanson; Jonathan Lipscomb; James Smith; Francis Novembre; Daria Hazuda; J Gerardo Garcia-Lerma; Walid Heneine
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

View more
  3 in total

Review 1.  Animal models in HIV-1 protection and therapy.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

2.  Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs.

Authors:  Mian-Er Cong; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  PLoS One       Date:  2016-11-02       Impact factor: 3.240

Review 3.  Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models.

Authors:  David S Khoury; Adam K Wheatley; Mitchell D Ramuta; Arnold Reynaldi; Deborah Cromer; Kanta Subbarao; David H O'Connor; Stephen J Kent; Miles P Davenport
Journal:  Nat Rev Immunol       Date:  2020-11-02       Impact factor: 53.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.